Adlai Nortye Partners With Lilly, Merck KGaA on AN4035 — Cetuximab Cancer Trial
Adlai Nortye today entered clinical trial collaboration and supply agreements with Eli Lilly and Germany's Merck to evaluate AN4035 with cetuximab. The ongoing global Phase I trial tests AN4035 alone or with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors. Lilly will supply cetuximab at no cost t